Evidence map›Paper›PMID 28629746›Full record

ArticleThe Journal of allergy and clinical immunology2018

Mechanisms of genotype-phenotype correlation in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency.

Daniel Petersheim, Michel J Massaad, Saetbyul Lee, Alessia Scarselli, Caterina Cancrini, Kunihiko Moriya, Yoji Sasahara, Arjan C Lankester, Morna Dorsey, Daniela Di Giovanni and 14 more

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Article
  2. Monogenic disorders of the TNF signalling pathway.Nature reviews. Rheumatology · 2026
    Review
  3. A Novel De NovoGenes · 2022
    Article
  4. Ectodysplasin A (EDA) Signaling: From Skin Appendage to Multiple Diseases.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of the NFκB-signaling pathway in cancer.OncoTargets and therapy · 2018
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 7 countries.

Daniel PetersheimDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
Michel J MassaadDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
Saetbyul LeeDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
Alessia ScarselliDivision of Immunology and Infectious Diseases, Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, and University of Rome Tor Vergata, Rome, Italy.
Caterina CancriniDivision of Immunology and Infectious Diseases, Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, and University of Rome Tor Vergata, Rome, Italy.
Kunihiko MoriyaDepartment of Pediatrics, Tohoku University, Tohoku, Japan.
Yoji SasaharaDepartment of Pediatrics, Tohoku University, Tohoku, Japan.
Arjan C LankesterDepartment of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Morna DorseyDivision of Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, Calif.
Daniela Di GiovanniImmunology Service, Ricardo Gutiérrez Children's Hospital, Buenos Aires, Argentina.
Liliana BezrodnikImmunology Service, Ricardo Gutiérrez Children's Hospital, Buenos Aires, Argentina.
Hidenori OhnishiDepartment of Pediatrics, Gifu University, Gifu, Japan.
Ryuta NishikomoriDepartment of Pediatrics, Kyoto University, Kyoto, Japan.
Kay TanitaDepartment of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan.
Hirokazu KaneganeDepartment of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan.
Tomohiro MorioDepartment of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan.
Erwin W GelfandImmunodeficiency Diagnosis and Treatment Program, Department of Pediatrics, National Jewish Health, Denver, Colo.
Ashish JainMerck Research Laboratories Boston, Boston, Mass.
Elizabeth SecordDivision of Allergy, Asthma, and Immunology, Children's Hospital of Michigan, Detroit, Mich.
Capucine PicardPediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital, Paris Descartes University, Paris, France.
Jean-Laurent CasanovaPediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital, Paris Descartes University, Paris, France; St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY.
Michael H AlbertDepartment of Pediatric Hematology and Oncology, Dr von Hauner University Children's Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Troy R TorgersonDepartment of Pediatrics, University of Washington School of Medicine, Seattle, Wash.
Raif S GehaDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: raif.geha@childrens.harvard.edu.
Boston Children's Hospital · USTokyo Medical and Dental University · JPDélégation Paris 5 · FRHospital General de Niños Ricardo Gutierrez · ARTohoku University · JPUniversity of Rome Tor Vergata · ITChildren's Hospital of Michigan · USGifu University · JPKyoto University · JPLeiden University Medical Center · NLLudwig-Maximilians-Universität München · DEMerck & Co., Inc., Rahway, NJ, USA (United States) · USNational Jewish Health · USUniversity of California, San Francisco · USUniversity of Washington · US

Funding

Regulation of IgA class switching in the intestinal mucosaP01AI061093 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CUNNINGHAM-RUNDLES, CHARLOTTE · 2004 to 2021
$29.8M
Mechanisms of disease in patients with I?B? mutationsR21AI124101 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI GEHA, RAIF SALIM · 2016 to 2017
$487k
NIAID NIH HHS P01 AI061093NIAID NIH HHS R21 AI124101
6 · The paper itself

Abstract

backgroundAutosomal dominant anhidrotic ectodermal dysplasia with immune deficiency (AD EDA-ID) is caused by heterozygous point mutations at or close to serine 32 and serine 36 or N-terminal truncations in IκBα that impair its phosphorylation and degradation and thus activation of the canonical nuclear factor κ light chain enhancer of activated B cells (NF-κB) pathway. The outcome of hematopoietic stem cell transplantation is poor in patients with AD EDA-ID despite achievement of chimerism. Mice heterozygous for the serine 32I mutation in IκBα have impaired noncanonical NF-κB activity and defective lymphorganogenesis.

objectiveWe sought to establish genotype-phenotype correlation in patients with AD EDA-ID.

methodsA disease severity scoring system was devised. Stability of IκBα mutants was examined in transfected cells. Immunologic, biochemical, and gene expression analyses were performed to evaluate canonical and noncanonical NF-κB signaling in skin-derived fibroblasts.

resultsDisease severity was greater in patients with IκBα point mutations than in those with truncation mutations. IκBα point mutants were expressed at significantly higher levels in transfectants compared with truncation mutants. Canonical NF-κB-dependent IL-6 secretion and upregulation of the NF-κB subunit 2/p100 and RELB proto-oncogene, NF-κB subunit (RelB) components of the noncanonical NF-κB pathway were diminished significantly more in patients with point mutations compared with those with truncations. Noncanonical NF-κB-driven generation of the transcriptionally active p100 cleavage product p52 and upregulation of CCL20, intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 (VCAM1), which are important for lymphorganogenesis, were diminished significantly more in LPS plus α-lymphotoxin β receptor-stimulated fibroblasts from patients with point mutations compared with those with truncations.

conclusionsIκBα point mutants accumulate at higher levels compared with truncation mutants and are associated with more severe disease and greater impairment of canonical and noncanonical NF-κB activity in patients with AD EDA-ID.

Indexed as

GenotypeSignal TransductionCarrier ProteinsChemokine CCL20Ectodermal DysplasiaGenetic Diseases, X-LinkedHEK293 CellsHumansImmunologic Deficiency SyndromesIntercellular Adhesion Molecule-1Interleukin-6NF-KappaB Inhibitor alphaNF-kappa B p52 SubunitPoint MutationPrimary Immunodeficiency DiseasesProto-Oncogene Mas11-cis-retinal-binding proteinCarrier ProteinsCCL20 protein, humanChemokine CCL20ICAM1 protein, humanIL6 protein, humanIntercellular Adhesion Molecule-1Interleukin-6MAS1 protein, humanNF-KappaB Inhibitor alphaNF-kappa B p52 SubunitNFKBIA protein, humanProto-Oncogene Mascanonical nuclear factor κB pathwayEctodermal dysplasia with immune deficiencyhematopoietic stem cell transplantationlymphorganogenesisNF-κB inhibitor αnoncanonical nuclear factor κB pathway

Identifiers

PMID28629746
PMCPMC5733640
OpenAlexW2626117183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.